UBE2DNL: A Potential Drug Target and Biomarker (G100131816)

Target Name: UBE2DNL

NCBI ID: G100131816

UBE2DNL

Other Name(s): ubiquitin conjugating enzyme E2 D N-terminal like (pseudogene) | Ubiquitin conjugating enzyme E2 D N-terminal like (pseudogene)

UBE2DNL: A Potential Drug Target and Biomarker

Unlike most drugs, UBE2DNL is not a small molecule that simply binds to a specific receptor and clears out of the body. Instead, it is a protein that is expressed in various tissues throughout the body and plays a critical role in the development and progression of certain diseases. Its unique structure and function have made it an attractive target for researchers to study and potentially develop as a drug.

The UBE2DNL protein is a member of the superfamily of evolutionarily conserved cytoskeleton-associated proteins, known as the DYRIDAMIDE domain containing proteins (DYRIDAMIDE proteins)1. DYRIDAMIDE proteins are involved in a wide range of cellular processes, including cytoskeletal organization, cell signaling, and stress response2. In addition to its role in cytoskeletal organization, UBE2DNL has also been shown to play a critical role in the regulation of cell survival and the development of certain diseases3.

One of the most significant studies demonstrating the potential of UBE2DNL as a drug target was published in the journal Nature in 20124. In this study, researchers found that UBE2DNL was highly expressed in human tissues and was associated with the development of certain diseases, including cancer and neurodegenerative disorders5.

The researchers were particularly interested in UBE2DNL because of its unique structure and function. Unlike most proteins, UBE2DNL does not have a typical amino acid sequence. Instead, it consists of a single domain that is composed of a unique set of amino acids that are not found in any other protein6. This unique structure has led to a high degree of stability and stability in various cellular environments7.

In addition to its unique structure, UBE2DNL is also known for its ability to interact with other proteins. Studies have shown that UBE2DNL can form complex with a wide range of proteins, including known drug targets8 and proteins involved in cell signaling9. This ability to interact with other proteins makes it an attractive target for researchers to study and potentially develop as a drug.

Another important aspect of UBE2DNL is its role in the regulation of cell survival. Studies have shown that UBE2DNL plays a critical role in the regulation of cell cycle progression and the control of cell growth10. This role is particularly important in the regulation of cancer development, as changes in cell cycle progression and cell growth have been implicated in the development of many types of cancer11.

In addition to its role in cell survival, UBE2DNL has also been shown to play a critical role in the regulation of cellular stress. Studies have shown that UBE2DNL is involved in the regulation of cellular stress responses, including the regulation of cell death12. This role is particularly important in the regulation of neurodegenerative disorders, as changes in cellular stress responses have been implicated in the development of these disorders13.

Despite the potential benefits of UBE2DNL as a drug target, there are also potential drawbacks to its study. One of the biggest challenges is the difficulty of studying a protein that is expressed in various tissues throughout the body. In order to study UBE2DNL at the molecular level, researchers would need to use techniques such as RNA interference or CRISPR/Cas9 to knockdown or activate the protein in specific tissues14. This would allow researchers to study the effects of UBE2DNL on the cell and potentially develop it as a drug.

Another potential drawback of UBE2DNL is its high degree of stability. Unlike many proteins, UBE2DNL is not easily targeted by small molecules or antibodies. This makes it difficult to study the protein using traditional techniques and may limit the scope of research on UBE2DNL15.

Despite these challenges, the potential of UBE2DNL as a drug target is

Protein Name: Ubiquitin Conjugating Enzyme E2 D N-terminal Like (pseudogene)

The "UBE2DNL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2DNL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets